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Background. Prior studies suggest that transgender women (TW) with human immunodeficiency virus (HIV) are less likely to 
be virally suppressed than cisgender women (CW) and cisgender men (CM). However, prior data are limited by small sample sizes 
and cross-sectional designs. We sought to characterize the HIV care continuum comparing TW to CW and CM in the United States 
and Canada.
Methods. We analyzed annual HIV care continuum outcomes by gender status from January 2001 through December 2015 
among adults (aged ≥18 years) in 15 clinical cohorts. Outcomes were retention in care and viral suppression.
Results. The study population included TW (n = 396), CW (n = 14 094), and CM (n = 101 667). TW had lower proportions 
retained in care than CW and CM (P < .01). Estimates of retention in care were consistently lower in TW, with little change over 
time within each group. TW and CW had similar proportions virally suppressed over time (TW, 36% in 2001 and 80% in 2015; CW, 
35% in 2001 and 83% in 2015) and were lower than CM (41% in 2001 and 87% in 2015). These differences did not reach statistical 
significance after adjusting for age, race, HIV risk group, and cohort.
Conclusions. TW experience challenges with retention in HIV care. However, TW who are engaged in care achieve viral sup-
pression that is comparable to that of CW and CM of similar age, race, and HIV risk group. Further research is needed to understand 
care engagement disparities.
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An estimated 1 in 5 transgender women (TW; individuals 
assigned male at birth who identify as women) in the United 
States are living with human immunodeficiency virus (HIV) 
[1, 2]. The Centers for Disease Control and Prevention (CDC) 
National HIV Surveillance System reported 1974 newly 
diagnosed cases of HIV in TW from 2009 through 2014, the 
most recent years for which data have been published [3]. 
Approximately 1 in 4 of these women were diagnosed with 
AIDS within 3  months of their HIV diagnosis, suggesting 
delayed engagement in HIV testing and care. Successful en-
gagement and retention in HIV care as well as viral suppression 
are critical to reducing morbidity and mortality among people 
living with HIV [4] and to reducing onward transmission [5]. 
The published literature on HIV care engagement among TW is 
limited. However, patient self-reported data suggest inequities 
in HIV care engagement [6], antiretroviral therapy adher-
ence [6,7], and viral suppression [7–9].
Cross-sectional studies based on medical records have 
found that TW have lower rates of viral suppression but sim-
ilar rates of retention in clinical care compared with cisgender 
(nontransgender) women (CW) and cisgender men (CM) living 
with HIV. In their most recent analysis of transgender people 
living with HIV, the CDC Medical Monitoring Project pooled 
population-representative medical record data from 2009 through 
2011 representing 5729 TW in the United States. They found no 
difference in receipt of antiretroviral prescriptions among TW 
compared with CM and CW [10]. However, a significantly lower 
proportion of TW had 100% self-reported antiretroviral dose ad-
herence relative to CM and CW (78% vs 87% and 83%, respec-
tively) and viral suppression (51% vs 61% and 57%, respectively). 
More than 8800 transgender individuals living with HIV received 
Ryan White HIV/AIDS Program services in 2017, including 7837 
TW [11]. TW were as likely as cisgender adults to be retained in 
care (78.2% vs 80.9%), but they were significantly less likely to 
have a suppressed viral load (80.9% vs 85.9%).
Many prior studies have been limited by cross-sectional 
designs and/or self-reported HIV outcomes. Data on changes 
in TW’s engagement in care over time are scant. Yehia and 
colleagues reported data from a 2001–2011 retrospective co-
hort that included 285 transgender patients from 13 HIV clinics 
across the United States [12]. They found no difference in the 
percentage of patient-years retained in HIV care, receiving an-
tiretroviral therapy, or being virally suppressed between trans-
gender and cisgender participants. However, these findings did 
not disaggregate TW from other transgender participants in the 
cohort.
In this study, we sought to address gaps in the literature on the 
HIV care continuum among TW in clinical care using data from 
the North American AIDS Cohort Collaboration on Research 
and Design (NA-ACCORD). NA-ACCORD is the largest on-
going cohort of people living with HIV in the United States and 
Canada, with more than 20 collaborating cohorts that contribute 
data on participants living with HIV. Fifteen of these cohorts 
were able to contribute data on transgender participants. We 
named this subcohort the North American Transgender Cohort 
Collaboration (NA-TRACC). Our objective in this study was 
to estimate retention in care and viral suppression among TW 
compared with CM and CW in NA-TRACC. We hypothesized 
that TW would be less likely to be retained in care and less likely 
to be virally suppressed compared with CW and CM. Based on 
known social and structural drivers of HIV infection [13, 14], 
we also hypothesized that TW who are racial/ethnic minorities, 
are younger, and engage in injection drug use (IDU) would be 
less likely to engage in care and achieve viral suppression than 
white, older, and noninjection drug using TW, respectively.
METHODS
The NA-ACCORD is the North American region of the 
International epidemiology Databases to Evaluate AIDS (IeDEA) 
project, supported by the National Institutes of Health. Details on 
this collaboration have been published previously [15]. Briefly, the 
NA-ACCORD consists of single- and multisite clinical and in-
terval cohorts that prospectively collect data on more than 180 000 
adults living with HIV (aged ≥18 years) from multiple sites in the 
United States and Canada [16]. Each cohort submits comprehen-
sive data on enrolled participants to the Data Management Core 
(University of Washington, Seattle), where the data undergo quality 
control, are harmonized across cohorts, and are transmitted to 
the Epidemiology/Biostatistics Core (Johns Hopkins University, 
Baltimore, MD), which conducted the analyses presented here. 
The human subjects research activities of the NA-ACCORD and 
each of the participating cohort studies have been reviewed and 
approved by their respective local institutional review boards 
and the Johns Hopkins School of Medicine. The Johns Hopkins 
Bloomberg School of Public Health Institutional Review Board 
approved the present study.
This retrospective, time-series analysis included adults from 
the 15 NA-TRACC that contribute US and Canadian clinical 
cohorts with access to electronic medical record data with 
transgender status from 1 January 2001 to 31 December 2015 
(Supplementary Table). Intersex adults (n = 2) and transgender 
men (n = 38) were excluded from this analysis as the focus of 
this study was TW.
Gender Status: Transgender Women, Cisgender Women, and 
Cisgender Men
Transgender status was captured using different approaches 
across the contributing cohorts, including presence of diag-
nosis codes for gender dysphoria, comparison of natal sex with 
reports of feminizing or masculinizing hormones from medica-
tion lists, gender identity queried at intake, and medical provider 
documentation in the clinical record [17]. These approaches 
were harmonized into a single variable that categorized gender 
status as TW, CW, CM, and transgender man. TW included 
participants who were assigned male sex at birth who had a di-
agnosis of gender dysphoria, were taking feminizing hormones, 
and/or were identified as women or TW by self-report or pro-
vider report in the medical record.
Outcomes: Retention in Care and HIV RNA Suppression
The proportion of participants retained in care and the propor-
tion with viral suppression were estimated in each calendar year 
from 2001 through 2015, applying a serial cross-sectional ap-
proach to the longitudinal data. Both measures used the same 
denominator: those who had at least 1 HIV clinic visit in the 
calendar year, based on encounter data. The numerator for the 
proportion retained in care was the number of participants with 
at least 2 HIV clinical visits more than 90 days apart in the cal-
endar year. This measure was shown to be an appropriate sur-
rogate for retention in care in prior NA-ACCORD studies [18] 
and mirrors definition used by the HIV/AIDS bureau of the US 
Health Resources Services Administration [19]. The numerator 
for the proportion of participants with viral suppression was the 
number of participants with an HIV RNA measurement ≤200 
copies/mL at the last measurement of the year.
Covariates
All covariates were collected at enrollment into the 
NA-ACCORD. Age in years was determined from year of birth. 
Race/ethnicity was categorized as white, black, Hispanic, or 
other. HIV risk group classification reflected the suspected 
mode of HIV acquisition categorized as IDU, sexual behavior, 
other (eg, hemophilia), and other/unknown.
Statistical Analyses
Differences in covariates among TW, CW, and CM were 
examined using a χ2 test (for differences in proportions), 
a t test (for differences in means), and the Kruskal-Wallis 
test (for a difference in medians). The annual proportions 
of participants retained in care and virally suppressed were 
estimated from 2001 through 2015. Because individuals 
could contribute information to more than 1 calendar year, 
the P value for trend was estimated using a log-binomial re-
gression model with generalized estimating equations (as the 
observations in each year are not independent), with an or-
dinal variable for calendar year, which tests the null hypo-
thesis that there is no change in the indicator over time. To 
determine if there was statistical evidence that the associa-
tion of gender status and the outcomes of interest changed 
over time, we used a nested model approach that allowed us 
to compare the fit statistics for models with and without the 
interaction terms using log binomial regression models with 
generalized estimating equations.
We restricted the analysis of gender status and the outcomes 
of interest to 2014 (the most recent year in which all 15 cohorts 
contributed data for the entire year). Log binomial regression 
for retention in care and modified Poisson regression for viral 
suppression (due to failed convergence of the log binomial) 
were used to estimate adjusted prevalence ratios (aPR) and 95% 
confidence intervals ([,]), accounting for age, race/ethnicity, 
history of IDU, and cohort.
Finally, we restricted the study population to only TW and 
used the same models to examine the associations of age, race/
ethnicity, and history of IDU with the outcomes of interest.
RESULTS
As listed in Table 1, the study population included TW 
(n = 396), CW (n = 14 094), and CM (n = 101 667). TW were 
younger at baseline (median, 36  years; interquartile range 
[IQR], 29, 43) compared with CW (40 years; IQR, 32, 47) and 
CM (44 years; IQR, 37, 52), with 36% of TW aged ≥40 years 
vs 49% of CW and 66% of CM. Among TW, 40% were black 
compared with 56% of CW and 36% of CM. Sexual behavior 
was the most common HIV acquisition risk among TW (79%) 
compared with CW (61%) and CM (45%).
TW demonstrated greater variability in estimates of reten-
tion in care, likely due to relatively small sample sizes. A lower 
proportion of TW were retained in care compared with CW 
and CM, with statistical evidence of a difference in trends 
in retention in care by gender (Figure 1; P value for interac-
tion = .0093). The retention in care estimates declined slightly 
over time for CW and CM (P values for trend: CW, P = .0003 
and CM, P  <  .0001). Estimates of retention in care were 
Table 1. Participant Characteristics in the First Year the Participant Had 1 Human Immunodeficiency Virus Care Visit, by Gender—North American AIDS 
Cohort Collaboration on Research and Design, 2001–2015
Characteristic
Transgender Women Cisgender Women Cisgender Men
(N = 396) (N = 14 094) (N = 101 667)
Age, y 
Mean (standard deviation) 37 (10) 40 (10) 44 (11)
Median (interquartile range) 36 (29–43) 40 (32–47) 44 (37–52)
Categorical (n, %)
  18–39 255 64 7214 51 34 755 34
  40–49 97 24 4408 31 34 768 34
  50–59 42 11 1961 14 23 097 23
  60–69 2 1 439 3 7110 7
  ≥70 … 0 72 1 1937 2
Race/ethnicity
 White 92 23 3405 24 44 632 44
 Black 160 40 7923 56 36 348 36
 Hispanic 85 21 919 7 9586 9
 Other 44 11 914 6 3798 4
 Unknown 15 4 933 7 7303 7
Human immunodeficiency virus acquisition risk
History of injection drug use 30 8 2878 20 18 947 19
 Sexual 314 79 8564 61 45 347 45
 Other 4 1 804 6 1137 1
 Unknown 48 12 1848 13 36 236 36
consistently lower in TW, with no statistical evidence of a trend 
(P value for trend: TW, P  =  .6144). The prevalence of TW 
retained in care did not differ from CM (aPR = 0.99 [0.90, 1.08]) 
after adjusting for age, race/ethnicity, HIV risk group, and co-
hort (Table 2). However, the prevalence of patients retained in 
care was greater in CW than CM (aPR = 1.03 [1.02, 1.05]).
All 3 groups showed substantial improvements in viral suppression 
from 2001 through 2015 (Figure 2; P values for trend: TW, P < .0001; 
CW, P < .0001; CM, P < .0001). CM had the highest proportion with 
viral suppression, and TW and CW had proportions that were similar 
to each other over time. Although differences in viral suppression by 
gender status were the greatest in 2001, this difference narrowed in 
more recent years (P for interaction, <.0001). Viral suppression did 
not differ by gender status in adjusted analyses (TW vs CM aPR = 0.96 
[0.89, 1.02]; CW vs CM aPR = 1.00 [0.98, 1.01]; Table 2).
As hypothesized, older age was associated with a greater likeli-
hood of being retained in care and having a suppressed viral load 
in unadjusted models among TW (Table 3). While differences 
by age were no longer significant in adjusted models, TW with 
an other/unknown HIV acquisition risk were significantly more 
Table 2. Prevalence Ratios for the Associations of Gender With Retention in Care and Viral Suppression—North American AIDS Cohort Collaboration on 
Research and Design, 2014
Gender N % PRa 95% CI aPRb 95% CI
Retained in Care (N = 23 354)
Transgender women 151 1 1.00 [.92, 1.10] 0.99 [.90, 1.08]
Cisgender women 4731 20 1.05 [1.04, 1.07] 1.03 [1.02, 1.05]
Cisgender men 18 427 79 Ref … Ref …
Suppressed (≤200 copies/mL) Human Immunodeficiency Virus Viral Load (N = 26 355)
Transgender women 173 1 0.93 [.86, .99] 0.96 [.89, 1.02]
Cisgender women 5171 20 0.96 [.95, .98] 1.00 [.98, 1.01]
Cisgender men 21 011 80 Ref … Ref …
Bold signifies the 95% CI does not include 1.0.
Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; PR, prevalence ratio; Ref, Reference category.
aThe PRs and 95% CIs were estimated using a log-binomial regression model.
bThe aPRs and 95% CIs were estimated using a log-binomial regression model (for retention in care) and a Poisson regression with robust variance model (for viral suppression) accounting 
for age, race/ethnicity, human immunodeficiency virus risk group, and cohort.
Figure 1. Proportion retained in care, by gender status, North American AIDS Cohort Collaboration on Research and Design, 2001–2015. Retention in care was defined 
according to the United States Health Services Resources Administration. The P values for trends in the outcomes over a calendar year were estimated using a log-binomial 
model with generalized estimating equations (GEE) and a continuous variable for calendar year, which tests the null hypothesis that there is no difference in the outcome 
over time and allows for repeated measurements from individuals. The P value for interaction of time and gender status was estimated using a nested model approach that 
allowed us to compare the fit statistics for models with and without the interaction terms using log-binomial regression models with GEE.
likely to be retained in care compared with those with sexual risk 
(aPR = 1.82 [1.24, 2.69]). There were no significant differences 
by race in either retention in care or viral suppression.
DISCUSSION
The majority of TW in NA-TRACC were black, younger than 
cisgender patients, and less likely to be retained in HIV care. 
Prior research indicates that black TW experience a dispropor-
tionate burden of HIV [10, 13]. Therefore, it was not surprising 
that the majority of TW in NA-TRACC were black. TW were 
younger than cisgender participants, and sexual contact was 
the most common risk category. While the younger age of TW 
in NA-TRACC could be due to earlier diagnosis and linkage 
to care, prior CDC testing event data suggest that TW acquire 
HIV infection at earlier ages [20, 21] but may be no more likely 
than cisgender populations to be tested for HIV [22]. CDC data 
also indicate that the majority of TW with newly positive HIV 
test results have been aged <30  years (56.3%), black (53.9%), 
and had condomless sex (67%) [20]. Given this context, our 
sociodemographic data suggest that young, black, sexually ac-
tive TW may be particularly vulnerable to HIV infection and 
should be prioritized for engagement in HIV testing, preven-
tion, and care.
We hypothesized that TW would be less likely than cisgender 
participants to be retained in care. Consistent with this 
hypothesis, TW demonstrated lower retention in care over time 
compared with cisgender patients. Transgender-specific barriers 
to engagement in care include fear of disclosure of transgender 
identity; poor treatment by staff, such as using the inappropriate 
name or pronoun; and provider lack of knowledge about trans-
gender health [23–25]. From 2012 through 2017, the US Health 
Services Resources Administration (HRSA) funded 9 sites in 4 
urban areas to implement innovative interventions designed to 
improve engagement in HIV care for TW of color [26]. None 
of these sites were NA-TRACC sites. While outcome data from 
the HRSA initiative have not yet been published, baseline data 
suggested that participants who received both their HIV care 
and gender-affirming care (eg, provision of hormones) from 
the same healthcare provider were more likely to be retained 
in care [27]. Emerging data support that TW frequently priori-
tize gender-affirming care over other health issues [28] and that 
meeting the gender-affirmation needs of TW living with HIV 
may be an effective way to improve care engagement [29].
We hypothesized that TW would be less likely to achieve viral 
suppression compared with cisgender participants. While TW 
in NA-TRACC were less likely to achieve viral suppression than 
CM in bivariate analyses, they had viral suppression that was 
similar to that of CW, and no significant difference was found 
by gender in adjusted analyses. One possible explanation for this 
finding could be that NA-TRACC sites provide gender-affirming 
Figure 2. Proportion with human immunodeficiency virus (HIV) RNA suppression (≤200 copies/mL), by gender status, North American AIDS Cohort Collaboration on 
Research and Design, 2001–2015. The last HIV RNA measurement was used if there were multiple measurements in a year for an individual. The P values for trends in the 
outcomes over a calendar year were estimated using a log-binomial model with generalized estimating equations (GEE) and a continuous variable for calendar year, which 
tests the null hypothesis that there is no difference in the outcome over time and allows for repeated measurements from individuals. The P value for interaction of time and 
gender status was estimated using a nested model approach that allowed us to compare the fit statistics for models with and without the interaction terms using log-binomial 
regression models with GEE.
care. Baseline data from a different multisite, longitudinal study 
on engaging TW of color in HIV care found that viral suppres-
sion was more common among TW whose HIV care provider 
also prescribed their gender-affirming hormones [30]. A study 
among transgender people living with HIV found that gender-
affirming and supportive attitudes by healthcare providers 
were associated with viral suppression, while making access to 
hormone therapy contingent upon antiretroviral therapy ad-
herence was associated with a lower likelihood of viral suppres-
sion [31]. In short, clinicians who provide both HIV care and 
gender-affirming hormones without requiring antiretroviral 
therapy adherence to get hormones see more success with viral 
suppression among their TW patients living with HIV. Data on 
gender-affirming hormone therapy use in NA-TRACC were 
not available for this analysis. However, these data are currently 
being collected by participating cohorts, and future analyses 
should be able to provide insight into the role gender-affirming 
hormone therapy may play in viral suppression for TW.
Contrary to our hypotheses, we found no significant 
differences in retention in care and viral suppression among 
TW based on age or race in adjusted analyses. TW with IDU 
as their primary HIV risk did not differ significantly in reten-
tion in care or viral suppression from TW with sexual risk. 
However, sample sizes for these analyses were relatively small 
(n = 151 for retention in care and n = 91 for viral suppres-
sion), resulting in limited power to detect statistically signif-
icant differences.
Given that the majority of TW in NA-TRACC were racial/
ethnic minorities and that TW were significantly younger 
than cisgender participants, strategies to engage young racial/
ethnic minorities should be transgender-inclusive and consider 
the intersecting barriers to care engagement that may exist 
Table 3. Associations of Age, Race/Ethnicity, and Human Immunodeficiency Virus Risk Group on Retention in Care and Viral Suppression Among 
Transgender Women in the North American AIDS Cohort Collaboration on Research and Design, 2014
Characteristics n % PRa 95% CI aPRb 95% CI
Retained in Care (N = 151)
Age, y
 18–39 94 62 0.86 [.70, 1.05] 0.81 [.66, 1.00]
 40–49 38 25 Ref … Ref …
 50–59 17 11 1.08 [.86, 1.36] 1.04 [.81, 1.32]
 60–69 2 1 1.23 [1.05, 1.43] 1.00 [.78, 1.30]
 ≥70 0 0 … … … …
Race/ethnicity
 White 33 22 Ref … Ref …
 Black 61 40 1.11 [.85, 1.44] 1.18 [.89, 1.56]
 Hispanic 41 27 1.08 [.82, 1.44] 1.18 [.88, 1.57]
 Other/Unknown 16 11 1.17 [.84, 1.61] 1.24 [.87, 1.76]
HIV acquisition risk
 IDU 5 3 1.07 [.69, 1.68] 1.06 [.64, 1.77]
Sexual behavior 133 88 Ref … Ref …
 Other/Unknown 13 9 1.14 [.88, 1.46] 1.82 [1.24, 2.69]
Suppressed (≤200 copies/mL) HIV Viral Load (N = 173)
Age (in years)
 18–39 112 65 0.86 [.74, 1.00] 0.83 [.72, .96]
 40–49 40 23 Ref … Ref …
 50–59 19 11 1.12 [1.00, 1.25] 1.14 [.99, 1.32]
 60–69 2 1 1.12 [1.00, 1.25] 1.31 [.96, 1.80]
 ≥70 … … … … … …
Race/ethnicity
 White 35 20 Ref … Ref …
 Black 76 44 0.83 [.69, 1.00] 0.80 [.62, 1.03]
 Hispanic 45 26 1.06 [.91, 1.23] 1.10 [.94, 1.27]
 Other/Unknown 17 10 1.00 [.81, 1.24] 0.99 [.78, 1.27]
HIV transmission risk
 IDU 7 4 1.05 [.77, 1.44] 0.95 [.69, 1.30]
Sexual behavior 152 88 Ref … Ref …
 Other/Unknown 14 8 1.14 [.97, 1.35] 1.20 [.83, 1.73]
Bold signifies the 95% CI does not include 1.0.
Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; HIV, human immunodeficiency virus; PR, prevalence ratio; Ref, reference category.
aThe PRs and 95% CIs were estimated using a log-binomial regression model.
bThe aPRs and 95% CIs were estimated using a Poisson regression with robust variance model accounting for age, race/ethnicity, cohort, and HIV risk group.
for populations with multiple marginalized identities. For ex-
ample, youth-focused programs to improve access, uptake, and 
adherence to antiretroviral therapy should incorporate ways 
to address transgender community concerns about potential 
drug–drug interactions between antiretroviral therapy and 
gender-affirming hormones [28]. Emerging data indicate that 
concentrations of tenofovir (a commonly used antiretroviral 
agent) are affected by the presence of exogenous estrogen, even 
when tenofovir is used as part of a fully suppressive combina-
tion regimen [32, 33]. While the clinical significance of this in-
teraction is unclear, it highlights the importance of considering 
transgender-specific issues in the provision of HIV care.
The main limitations of the study are related to measure-
ment of gender status and sample size. Transgender status 
was ascertained in different ways across the 15 contributing 
cohorts and typically collected at a single time point. Therefore, 
some participants may have been misclassified, for example, 
if they did not disclose their transgender identity, if it was not 
documented in the medical record, or if they did not identify as 
transgender until some time after the enrollment period. It is 
unlikely that such misclassification would significantly impact 
the findings given the small numbers of TW in comparison to 
CM and CW. This is one of the largest studies of TW in the 
United States and Canada; however, the relatively small sample 
size limited precision and the ability to adjust for numerous po-
tential confounders. It is possible that the sample size will grow 
over time as more TW are identified in existing cohorts and if 
additional cohorts are able to collect data on gender identity to 
contribute to NA-TRACC. With a larger number of transgender 
participants, estimates will be more stable, and more complex 
statistical analysis will be possible.
While our definition for retention in care was consistent 
with the Department of Health and Human Services defini-
tion, alternative ways of operationalizing care engagement (eg, 
based on missed visits vs kept visits) may have yielded different 
results [34]. Viral suppression was likely overestimated in all 3 
groups as the denominator was limited to those who had an 
HIV primary care visit in the calendar year. The study is lim-
ited by lack of contextual information on the timing of gender 
transition, the prescription and/or use of gender-affirming hor-
mone therapy, colocation of HIV and gender-affirming medical 
care, and structural factors such as poverty that may contribute 
to disparities in HIV outcomes. Future studies in NA-TRACC 
should collect this information systematically.
In the face of mounting data on the burden of HIV among TW, 
it is important to ensure equitable access to HIV care and treat-
ment. The HIV care continuum is an important epidemiologic 
tool that allows us to monitor disparities and identify where 
interventions are needed. The creation of NA-TRACC and 
analysis of data disaggregated by gender have been important 
steps toward ascertaining and addressing inequities in HIV 
outcomes among TW. Further research with larger numbers 
of transgender participants and inclusion of contextual data 
are necessary to inform effective interventions that ensure all 
people living with HIV have the opportunity to achieve their 
best health.
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